Skip to main content
. 2024 Sep 3;15:7666. doi: 10.1038/s41467-024-51453-z

Fig. 3. Characterization of EBOV-specific T-cell responses induced by the three vaccine strategies on day (D)14, D70, and month 12 after vaccination.

Fig. 3

A Total cytokine (IFN-γ ± IL-2 ± MIP1β ± TNF) levels (sum of the Boolean gates) produced by EBOV-specific CD4+ or CD8+ T cells from the Placebo (grey, n = 76), Ad26-MVA (red, n = 79), rVSV (blue, n = 27), and rVSV-booster (green, n = 9) groups after in-vitro stimulation on D14, D70, and month 12 post-prime vaccination. Each dot represents an individual value of total cytokine. Results are presented with the background subtracted. The box plots show the median (middle line) and the first and third quartiles (boxes), and the whiskers show 1.5 fold the interquartile range (IQR) above and below the box. Bivariate model was used for inter-arm comparisons of total cytokine levels of active vaccine groups (rVSV group, rVSV-booster group, and Ad26-MVA group) vs placebo group (grey). FDR (Benjamini-Hochberg) method was used to adjust for test multiplicity for each arm comparison separately. The exact p-value for CD4 at D70 in the comparison between the placebo group (grey) and the Ad26-MVA group (red) is p = 5.5e-08. B Functional composition of EBOV-specific CD4+ T-cell responses induced by the Ad26-MVA vaccine on D14 and D70 and by the rVSV-booster vaccine on D70. Responses are color coded according to the combination of cytokines produced. The arcs identify cytokine-producing subsets (IFN-γ, IL-2, MIP-1b and TNF) within the CD4+ and CD8+ T-cell populations. Source data are provided as a Source Data file.